The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

Ozempic and Wegovy have proven remarkably effective for obesity and diabetes management. But their cost is straining insurance budgets. ScienceDaily reports that covering these drugs for all eligible patients could overwhelm coverage plans—pushing some patients toward cheaper, compounded versions that researchers warn may carry serious safety risks. The gap highlights a fundamental problem: breakthrough medicine that works, but a system too constrained to pay for it.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton